arrow
J

Jill Corre

université toulouse iii-paul sabatier
H指数:43
被引数:7,818

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Publisher Correction: Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

Publisher更正:新诊断接受四联疗法治疗的多发性骨髓瘤的微小残留病分子预测因子

2026-11-030
OAAI
Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

新诊断接受四联疗法治疗的多发性骨髓瘤中微小残留病的分子预测因子

2026-10-190
OAAI
Subcutaneous isatuximab by on-body-injector plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma: ISASOCUT study

皮下注射isasutuximab(通过自体注射器)联合硼替佐米、来那度胺和地塞米松治疗新诊断的移植不合格多发性骨髓瘤:ISASOCUT研究

2026-10-090
OAAI
Longitudinal assessments of MRD in high-risk newly diagnosed transplant-ineligible multiple myeloma in the BENEFIT study (IFM2020-05)

BENEFIT研究(IFM2020-05)中高危初诊非移植候选多发性骨髓瘤的MRD纵向评估

2026-10-050
OAAI
Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma

炎症性骨髓微环境削弱达拉木单抗-来那度胺在多发性骨髓瘤中的治疗效果

2026-09-050
OAAI
Clinical outcomes of newly diagnosed myeloma patients with SLIM criteria : a subgroup analysis of the CASSIOPEIA study

新诊断多发性骨髓瘤患者SLIM标准下的临床结局:CASSIOPEIA研究中的亚组分析

Leukemia
IF13.4
2026-08-130
PRE
Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial

Cyclin D1过表达多发性骨髓瘤的反应特征和长期结局:来自CASSIOPEIA试验的见解

2026-07-030
OAAI
Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma

CASSIOPEIA患者表达谱优化了多发性骨髓瘤中MRD阴性的预后价值

2026-07-020
OAAI
PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma

PKMYT1是del(17p)高危多发性骨髓瘤的可靶向弱点

Blood
IF23.1
2026-06-050
PRE
FDG-PET Medullary Total Tumor Volume Highlights High-Risk Newly Diagnosed Multiple Myeloma Patients in CASSIOPEIA Trial

FDG-PET骨髓总肿瘤体积在CASSIOPEIA试验中凸显高风险新诊断多发性骨髓瘤患者

2026-03-310
OAAI
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma

多模态抗原逃逸以GPRC5D-targeted多发性骨髓瘤中的T细胞接合器

2026-01-150
OAAI
DIS3 licenses B cells for plasma cell differentiation in humans

DIS3许可b细胞用于人类的浆细胞分化

2025-11-250
OAAI
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience

35年专注于高剂量疗法和自体干细胞移植的学术研究:法国骨髓瘤研究组(IFM)的经验

2025-10-240
OA
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study

减瘤策略在髓外和/或高肿瘤负荷RRMM患者接受抗BCMA/CD3双特异性抗体治疗前:一项回顾性队列研究

2025-10-210
OA